CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Alnylam Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Alnylam Pharmaceuticals, Inc.
675 W Kendall St
Phone: (617) 551-8200p:617 551-8200 CAMBRIDGE, MA  02142-1168  United States Ticker: ALNYALNY
Business Summary
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Amy W.Schulman 63 1/5/2023 7/1/2014
Chief Executive Officer, Director Yvonne L.Greenstreet 61 1/1/2022 9/19/2016
Chief Financial Officer, Executive Vice President Jeffrey V.Poulton 56 8/13/2019 8/13/2019
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Sirna Therapeutics, Inc. 185 Berry Street San Francisco CA United States

Business Names
Business Name
ALNY
Alnylam (Bermuda) Ltd.
Alnylam Argentina Srl
21 additional Business Names available in full report.

General Information
Number of Employees: 2,100 (As of 12/31/2023)
Outstanding Shares: 125,933,946 (As of 3/22/2024)
Shareholders: 24
Stock Exchange: NASD
Federal Tax Id: 770602661
Fax Number: (617) 551-8101


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024